<DOC>
	<DOCNO>NCT00156715</DOCNO>
	<brief_summary>The purpose study examine efficacy quetiapine ( Seroquel ) reduce substance use person diagnose schizophrenia . The primary hypothesis quetiapine treatment associate decrease substance use .</brief_summary>
	<brief_title>Efficacy Quetiapine Treatment Patients With Schizophrenia Comorbid Substance Use Disorder</brief_title>
	<detailed_description>Comorbid alcohol/substance use disorder ( SUD ) schizophrenia major concern , view high frequency SUD among patient schizophrenia difficulty manage patient . Though antipsychotic medication effective reduce symptom impairment person schizophrenia , typical antipsychotic agent limited value control alcohol/substance use patient . Extrapyramidal , dysphoric side effect conventional neuroleptic may actually promote use substance attempt counteract effect . Novel antipsychotic radically alter treatment expectation outcomes patient severe form schizophrenia . With great availability novel agent clinical practice , note benefit also extend specific subgroup patient include patient comorbid SUD . Several retrospective study demonstrate decrease comorbid substance use patient schizophrenia treat clozapine . There little data available , however , efficacy quetiapine patient schizophrenia comorbid SUD . Its receptor profile , include weak Dopamine2 ( D2 ) receptor block ability substantial effect noradrenergic receptor , make logical antipsychotic use comorbid population . The study open-label investigation efficacy quetiapine group 30 patient schizophrenia comorbid substance use disorder . Patients diagnose schizophrenia schizoaffective disorder comorbid substance use disorder switch quetiapine 12 week . We hypothesize quetiapine treatment associate decrease substance use . Moreover , hypothesize measure symptom , cognition quality life also improve baseline assessment patient treat quetiapine . Data suggest beneficial effect quetiapine confirm prospective double-blind study . This pilot investigation provide preliminary data effect size use design subsequent investigation .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Age 1865 Schizophrenia schizoaffective disorder Meets Structured Clinical Interview Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( SCID ) criterion substance use disorder ( alcohol use disorder [ AUD ] ; abuse dependence ) Active substance use least 8 day 4 week prior randomization . Current treatment antipsychotic medication . Able provide inform consent , case patient legal court appoint guardian willing give assent , consent guardian . Not actively suicidal . Current treatment , decanoate antipsychotic , clozapine , dose quetiapine approve team investigator . Individuals treat depot antipsychotic must wait end injection cycle start study medication . Currently pregnant , plan become pregnant , unwilling use acceptable form birth control . Currently reside residential program design treat substance use disorder . Treatment baseline psychotropic agent propose curtail substance use . Patients , opinion investigator , judge unsuitable participate study . Unable take part assessment meaningful way Hypersensitivity/intolerance quetiapine Serious , unstable medical condition Participation clinical trial investigational drug within 30 day baseline visit , concurrent participation treatment study psychosocial intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Quetiapine</keyword>
	<keyword>Seroquel</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Dual Diagnosis</keyword>
	<keyword>Substance Abuse</keyword>
	<keyword>Alcohol Abuse</keyword>
</DOC>